IPP Bureau

Dabur India updates on Q1 FY25
Dabur India updates on Q1 FY25

By IPP Bureau - July 06, 2024

Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25

Biogen completes acquisition of HI-Bio
Biogen completes acquisition of HI-Bio

By IPP Bureau - July 06, 2024

Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study

FDA approves Roche’s Vabysmo PFS for three leading causes of vision loss
FDA approves Roche’s Vabysmo PFS for three leading causes of vision loss

By IPP Bureau - July 06, 2024

Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness

Merck inks MoU with Afrigen Biologics for development of mRNA vaccine technology platform
Merck inks MoU with Afrigen Biologics for development of mRNA vaccine technology platform

By IPP Bureau - July 05, 2024

Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization

GSK and CureVac restructure collaboration into new licensing agreement
GSK and CureVac restructure collaboration into new licensing agreement

By IPP Bureau - July 05, 2024

CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced

Cardiological Society of India releases first Indian guidelines for dyslipidemia management
Cardiological Society of India releases first Indian guidelines for dyslipidemia management

By IPP Bureau - July 05, 2024

Dyslipidemia is a critical risk factor for cardiovascular diseases

Briefs: Alembic Pharmaceuticals  and Relonchem
Briefs: Alembic Pharmaceuticals and Relonchem

By IPP Bureau - July 05, 2024

Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025

Evonik appoints Yann d’Herve as new head of Health Care business line
Evonik appoints Yann d’Herve as new head of Health Care business line

By IPP Bureau - July 04, 2024

Yann d’Hervé takes over responsibility for the Health Care business at Evonik, effective July 1

Health Ministry issues advisory to states in view of zika virus cases from Maharashtra
Health Ministry issues advisory to states in view of zika virus cases from Maharashtra

By IPP Bureau - July 04, 2024

States urged to maintain a state of constant vigil through screening of pregnant women for Zika virus infection and monitoring the growth of foetus of expecting mothers who tested positive for Zika

Dr. B.N. Gangadhar appointed as Chairperson of the National Medical Commission
Dr. B.N. Gangadhar appointed as Chairperson of the National Medical Commission

By IPP Bureau - July 04, 2024

Dr. Sanjay Behari, Director of Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, as the President of the Medical Assessment and Rating Board

Cupid Partners with SAP to Implement Advanced ERP System, SAP S/4HANA Cloud
Cupid Partners with SAP to Implement Advanced ERP System, SAP S/4HANA Cloud

By IPP Bureau - July 03, 2024

The integration of SAP S/4HANA Cloud will equip Cupid Limited with a comprehensive suite of integrated applications,

Aster Pharmacy to provide free random Blood Sugar and Blood Pressure check-ups at all its pharmacy outlets
Aster Pharmacy to provide free random Blood Sugar and Blood Pressure check-ups at all its pharmacy outlets

By IPP Bureau - July 03, 2024

The initiative aims to empower individuals to take proactive steps towards monitoring their health

Aster Whitefield Hospital and government partner for free epilepsy camp in Kolar
Aster Whitefield Hospital and government partner for free epilepsy camp in Kolar

By IPP Bureau - July 03, 2024

The initiative aimed to reach and support individuals suffering from epilepsy through early detection and effective disease management

Sipavibart EMA regulatory submission accepted under accelerated assessment for COVID-19 prevention
Sipavibart EMA regulatory submission accepted under accelerated assessment for COVID-19 prevention

By IPP Bureau - July 03, 2024

Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population

Avallano appoints Michael A. Ibara as Chief Strategy Officer
Avallano appoints Michael A. Ibara as Chief Strategy Officer

By IPP Bureau - July 03, 2024

Ibara will drive AI-powered clinical research innovation

Latest Stories

Interviews

Packaging